United Therapeutics Corporation
UTHR
$538.84
$5.901.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 783.30M | 781.50M | 790.20M | 799.50M | 798.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 783.30M | 781.50M | 790.20M | 799.50M | 798.60M |
| Cost of Revenue | 99.50M | 133.40M | 103.40M | 100.90M | 87.60M |
| Gross Profit | 683.80M | 648.10M | 686.80M | 698.60M | 711.00M |
| SG&A Expenses | 206.70M | 184.10M | 189.90M | 181.80M | 190.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 452.50M | 455.70M | 432.80M | 410.20M | 412.40M |
| Operating Income | 330.80M | 325.80M | 357.40M | 389.30M | 386.20M |
| Income Before Tax | 372.70M | 318.30M | 444.00M | 438.00M | 408.40M |
| Income Tax Expenses | 39.70M | 43.40M | 79.70M | 99.30M | 98.90M |
| Earnings from Continuing Operations | 333.00M | 274.90M | 364.30M | 338.70M | 309.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 333.00M | 274.90M | 364.30M | 338.70M | 309.50M |
| EBIT | 330.80M | 325.80M | 357.40M | 389.30M | 386.20M |
| EBITDA | 355.00M | 348.40M | 380.20M | 411.20M | 407.30M |
| EPS Basic | 7.82 | 6.32 | 8.41 | 7.73 | 6.86 |
| Normalized Basic EPS | 5.27 | 5.46 | 5.75 | 6.18 | 6.02 |
| EPS Diluted | 7.27 | 5.82 | 7.70 | 7.16 | 6.41 |
| Normalized Diluted EPS | 4.90 | 5.03 | 5.26 | 5.72 | 5.62 |
| Average Basic Shares Outstanding | 42.60M | 43.50M | 43.30M | 43.80M | 45.10M |
| Average Diluted Shares Outstanding | 45.80M | 47.20M | 47.30M | 47.30M | 48.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |